Rescue Medications

Phase 3

Merck & Co.

Rescue Medications is one of 94 therapeutic programs targeting Lung Neoplasm. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Lung NeoplasmRecruiting

Cervical CancerRecruiting

Gastroesophageal AdenocarcinomaRecruiting

Malignant NeoplasmRecruiting

Ovarian NeoplasmsRecruiting

Small Cell Lung Cancer Extensive StageRecruiting

Lung NeoplasmPhase 2

Recruiting

Cervical CancerPhase 3

Recruiting

Gastroesophageal AdenocarcinomaPreclinical

Recruiting

Malignant NeoplasmPhase 2

Recruiting

Ovarian NeoplasmsPhase 3

Recruiting

Small Cell Lung Cancer Extensive StagePreclinical

Recruiting

Competition

Competitive Landscape

380 competitors in Cervical Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

48 2

Paraplatin

AAvyxa

Phase 3

38 3

Avastin

BBio-Thera Solutions

Phase 3

25 4

Gemzar

Johnson & Johnson

Phase 3

8 5

Camptosar

Pfizer

Phase 3

4 6

Imfinzi

AstraZeneca

Phase 3

1 7

Trexall

Alnylam Pharmaceuticals

Phase 3

1 8

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

4 9

Alimta

EEagle Vision Pharmaceutical Corp.

Phase 3

4 10

Adrucil

EElorac, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Malignant Neoplasm

NCT06979596

Q3 2030

PreclinicalRecruiting

Gastroesophageal Adenocarcinoma

NCT06445972

Q4 2030

PreclinicalRecruiting

Small Cell Lung Cancer Extensive Stage

NCT07227597

Q4 2031

Phase 3Recruiting

Cervical Cancer

NCT07216703

Clinical

Trials by Indication[1]

Small Cell Lung Cancer Extensive Stage1 trial

A Phase 1b/2 Open-label Study Evaluating Different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-Based Regimens in First-line Extensive Stage Small Cell Lung Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07227597·170 enrolled

Malignant Neoplasm1 trial

A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06979596·250 enrolled

Lung Neoplasm1 trial

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06780098·144 enrolled

Cervical Cancer1 trial

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07216703·1,023 enrolled

Gastroesophageal Adenocarcinoma1 trial

A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06445972·210 enrolled

1 more indication

Ovarian Neoplasms1 trial

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT07318558·900 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Rescue Medications. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Rescue Medications. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Merck & Co.

Rescue Medications

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2030

Q4 2030

Q4 2031

Trials by Indication[1]

Small Cell Lung Cancer Extensive Stage1 trial

Malignant Neoplasm1 trial

Lung Neoplasm1 trial

Cervical Cancer1 trial

Gastroesophageal Adenocarcinoma1 trial

Ovarian Neoplasms1 trial

References

Drug Info

Quick Facts

Related News